Strontium Ranelate has a more positive influence than alendronate on distal tibia cortical and trabecular bone microstructure in women with postmenopausal osteoporosis : OC31

Détails

ID Serval
serval:BIB_A22ADF9B8FCF
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Strontium Ranelate has a more positive influence than alendronate on distal tibia cortical and trabecular bone microstructure in women with postmenopausal osteoporosis : OC31
Titre de la conférence
9th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
Auteur⸱e⸱s
Rizzoli R., Felsenberg D., Laroche M., Seeman E., Krieg M.A., Frieling I., Thomas T., Delmas P.D.
Adresse
Athens, Greece, March 19-21, 2009
ISBN
0937-941X
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
20
Série
Osteoporosis International
Pages
S15
Langue
anglais
Notes
Strontium ranelate (SR) and alendronate (ALN) are anti-osteoporotic
agents with antifracture efficacy against vertebral and non-vertebral
fractures. Whereas ALN is a pure bone resorption inhibitor, SR,
in vitro, increases bone formation and decreases bone resorption.
For the first time, we non-invasively evaluated and compared the effects
of SR and ALN on bone microstructure, a component of bone
quality, hence of bone strength, in osteoporotic women.
Eighty-eight women ≥50 years with postmenopausal osteoporosis
were randomised to SR 2g/day or ALN 70mg/week for 2
years. Microstructure of weight-bearing bone distal tibia was assessed
by high-resolution computerized tomography (HR-pQCT)
after 3, 6, 12, 18 and 24 months of treatment. A planned interim
statistical analysis was performed after 1 year in the intention-totreat
population (patients with a baseline and post-baseline HRpQCT
value, n=85). Primary endpoint was HR-pQCT variables
relative changes from baseline, secondary endpoints included
lumbar spine hip areal BMD and bone turnover markers.
Baseline characteristics were similar in both groups: age:
63.7±7.4 years; lumbar and hip T-Score: ‑2.7±0.9 g/cm² and -
2.0±0.8 g/cm², respectively. After 1 year of treatment, aBMD increases
were similar to results from pivotal trials (L1-L4: +5.7%
and +5.1%; total hip: +3.3% and +2.2%, in SR and ALN groups,
respectively). For bone microstructure, mean increases of +5.3%
(p<0.001) for C.Th, +2.0% (p=0.002) for BV/TV and +2.1%
(p=0.002) for trabecular density were found in SR group, compared
to no change in ALN group (1.3% p=0.130; 0.6% p=0.725
and 0.6% p=0.645, for corresponding variables, respectively),
with thus a significant between-group difference in favour of SR
(p=0.045, p=0.048 and p=0.034, for C.Th, BV/TV and trabecular
density, respectively). Improvement in microstructure was associated
in SR group with significant decrease in heterogeneity of
trabecular network (-3.6±8.6%, p=0.007). No between-group difference
was observed in cortical density. For bone turnover markers,
between-group differences were statistically significant at all
time-points, with a +5% increase in bALP and a -7% decrease in
sCTX in the SR group, compared to decreases of -35% and -58%
in the ALN group.
In conclusion, strontium ranelate had significantly higher effects
than alendronate on distal tibia microstructure including
cortical and trabecular variables, in women with postmenopausal
osteoporosis after one year of treatment.
Web of science
Création de la notice
24/03/2010 14:51
Dernière modification de la notice
20/08/2019 15:08
Données d'usage